November 10, 2016
Bristol-Myers to develop Nitto's investigational anti-fibrosis drug
Bristol-Myers gets exclusive worldwide rights to develop Nitto’s investigational anti-fibrosis drug
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Francis Cuss
October 15, 2015
BMS – Five Prime Agreement
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. have announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications.